Orphapacket:
  AverageAgeOfOnsets:
    AverageAgeOfOnset:
    - value: Adult
  Childs:
  - Child:
      Genes:
      - Gene:
          ExternalReferences:
          - Reference: '11905'
            Source: HGNC
          - Reference: '603612'
            Source: OMIM
          Label: TNF receptor superfamily member 10b
          Symbol: TNFRSF10B
      - Gene:
          ExternalReferences:
          - Reference: '9588'
            Source: HGNC
          - Reference: '601728'
            Source: OMIM
          Label: phosphatase and tensin homolog
          Symbol: PTEN
      - Gene:
          ExternalReferences:
          - Reference: '6062'
            Source: HGNC
          - Reference: '601566'
            Source: OMIM
          Label: inhibitor of growth family member 1
          Symbol: ING1
      Label: Squamous cell carcinoma of salivary glands
      ORPHAcode: '500481'
  DisorderType:
    PURL: http://www.orpha.net/ORDO/Orphanet_377788
    value: Disease
  Genes:
  - Gene:
      ExternalReferences: []
      Name: protein kinase D1
      Symbol: PRKD1
  Label: Malignant epithelial tumor of salivary glands
  ORPHAcode: '276145'
  ORPHApacketId: '276145'
  PURL: http://www.orpha.net/ORDO/Orphanet_276145
  Parents:
  - Parent:
    - Label: Rare tumor of salivary glands
      ORPHAcode: '276142'
  Prevalences:
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Austria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Germany
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Iceland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Ireland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Latvia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Malta
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Norway
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Poland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Portugal
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Slovakia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Slovenia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Spain
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Switzerland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Netherlands
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: United Kingdom
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Belgium
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Bulgaria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Croatia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Czech Republic
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Estonia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Finland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Italy
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Lithuania
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  TextSection:
    Contents: Malignant epithelial tumor of salivary glands is a rare neoplastic disease
      characterized by the presence of a tumor located in the parotid sublingual submandibular
      and/or minor salivary glands which presents with a wide spectrum of clinical
      features depending on the location size and type of salivary gland involved
      ranging from clinically asymptomatic slow-growing painless mass(es) that may
      or may not be fixed to underlying skin or muscles to rapidly growing mass(es)
      associated with pain facial weakness/nerve palsy otorrhoea dysphagia palatal/parapharyngeal
      fullness nasal obstruction/bleeding voice hoarseness/change dyspnea trismus
      palate bone erosion telangiectasia mucosal/skin ulceration and/or cervical adenopathy.
    TextSectionType: Definition
  copyright: Orphanet (c) 2021
  creationDate: '2021-08-17 17:32:38'
  version: 1.3.7 / 4.1.7 [2020-12-03] (orientdb version)
